6919:TWSECaliway Biopharmaceuticals Co Ltd Analysis

At TWD 110.50, CALIWAY BIOPHARMACEUTICALS CO L shows no decisive moving-average alignment, leaving the trend neutral. Over a rolling month the price has gained 12.0%. Momentum indicators put RSI at 56.9 (neutral) with MACD reading bullish. Price has been bracketed by support at TWD 97.50 and resistance at TWD 116.50.
The shares look undervalued, trading on 20.6 times earnings below a sector average of 29.9. Analyst price targets sit 117.2% above the current price.
Risk comes out at 7 of a possible 10, a elevated reading. With 30-day volatility of 57.4%, a beta of 0.60 and a maximum drawdown of 69.5%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 2 out of 10.